Develops blood-based DNA tests for cancer and genetic diseases.
Jun 2026Revenue $2.71B/yrExpenses $3.00B/yr
No trend
Figures by year
When will Natera be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $2.71B and expenses $3.00B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.31B | $2.62B | −$310M |
| Dec 2024 | $1.70B | $1.92B | −$222M |
| Dec 2023 | $1.08B | $1.53B | −$446M |
| Dec 2022 | $820M | $1.36B | −$541M |
| Dec 2021 | $625M | $1.09B | −$468M |
| Dec 2020 | $391M | $607M | −$216M |
| Dec 2019 | $302M | $419M | −$116M |
| Dec 2018 | $258M | $372M | −$115M |
| Dec 2017 | $210M | $345M | −$135M |
| Dec 2016 | $213M | $314M | −$101M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.